Wayne Koberstein
Contributor at Life Science Leader
Writer and Editor at Freelance
Writer. Own my opinions.
Articles
-
Jul 16, 2024 |
lifescienceleader.com | Wayne Koberstein
By Wayne Koberstein, Executive Editor, Life Science Leader Follow Me On Twitter @WayneKoberstein To protect and restore neuronal networks by enhancing natural repair processes. Snapshot Athira Pharma takes a small-molecule approach to targeting the neurotrophic hepatocyte growth factor (HGF) system for neurodegenerative diseases.
-
Mar 29, 2024 |
lifescienceleader.com | Wayne Koberstein
By Wayne Koberstein, Executive Editor, Life Science Leader Follow Me On Twitter @WayneKoberstein Resalis Enters the Widening Space of Weight Loss Discovery and accident are two words married at the hip. If you’re in the business of discovery, you should prepare for the fortunate accident, the kind that shows a pathway to something new and beneficial, one that takes you away from your original goal entirely and guides you thereafter toward a brand new destination.
-
Mar 1, 2024 |
lifescienceleader.com | Wayne Koberstein
By Wayne Koberstein, Executive Editor, Life Science Leader magazineFollow Me On Twitter @WayneKoberstein Inozyme’s Leader Shares Informed Views In the decades since the United States passed the Orphan Drug Act in 1983, its policies have succeeded in raising the number of drugs developed for rare diseases. Incentives in the Act were so effective, in fact, orphan drugs may have replaced blockbusters as the driving force of biopharma.
-
Feb 27, 2024 |
lifescienceleader.com | Wayne Koberstein
By Wayne Koberstein, Executive Editor, Life Science Leader magazineFollow Me On Twitter @WayneKoberstein Targeting the continuing need for HPV treatment with a topical antiviral. SNAPSHOT Antiva Biosciences is developing a new drug, coded ABI-2280, for treating Human Papilloma Virus (HPV)-related diseases, including precancerous conditions. ABI-2280 is a prodrug of an acyclic nucleoside phosphonate, formulated to improve safety as well as enhance deliverability as a topical medicine.
-
Feb 1, 2024 |
lifescienceleader.com | Wayne Koberstein
By Wayne Koberstein, Executive Editor, Life Science Leader magazineFollow Me On Twitter @WayneKoberstein Developing a potential small molecule breakthrough to challenge the biopharma paradigm. SNAPSHOT Promontory Therapeutics aims not only for the kind of innovation that improves the action of a drug class, but also for a revolution in how a drug accomplishes that action.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 101K
- DMs Open
- No
No, free speech also applies to publications. The current radical right wants to reject the ideological balance PBS has displayed for years and silence any anti-Trump content on the network permanently.
from “free speech means I can say what I want” (correct) to “free speech means you have to listen to me” (incorrect) to, finally, “free speech means you must be forced by law to fund my writing career” (absolutely insane). not interested, but thanks for playing.
RT @joshi: This is great: @maitlis asks @Sacha_Lord ‘why on earth’ he threatened to sue us. In response he lies about the Arts Council (th…
Frown, squint your eyes, wear inscrutable facial hair. But whatever you say, keep it stupid.
I can't believe that JD Vance just said this on Fox News. Holy Hell!!! https://t.co/VIO1k8JKqj
